source
- Sofinnova Partners raises €725 million for second crossover fund targeting late-stage European biotech firmsSofinnova Partners announced the closing of its second crossover fund with €725 million ($815 million) in commitments. The fund is designed to fill the financing gap for late-stage European biopha…
- San Diego’s Seawolf Therapeutics raises $100M to develop non-viral gene therapies for obesity, muscle loss and osteoporosisSan Diego‑based Seawolf Therapeutics announced it has closed a $100 million financing round to fund its platform for non‑viral gene therapies. The company says its approach tackles a long‑standing…Endpoints · 2h agoDealPositive